Mackenzie Financial
RNAC icon

Mackenzie Financial’s Cartesian Therapeutics RNAC Stock Holding History

Mackenzie Financial’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-923
Closed -$26.2K – 1568
2023
Q3 		$26.2K Hold
923
– – ﹤0.01% 1444
2023
Q2 		$31K Buy
923
+393
+74% +$14.1K ﹤0.01% 1487
2023
Q1 		$22.1K Buy
+530
New +$24.9K ﹤0.01% 1479

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mackenzie Financial's RNAC Position: Q4 2023 in Review

Mackenzie Financial sold out of Cartesian Therapeutics (RNAC) in Q4 2023, closing a stake of 923 shares — an estimated $26.2K sold.

Mackenzie Financial first reported a position in RNAC in Q1 2023 and held it in 3 quarters. The position peaked at $31K in Q2 2023. 80 funds tracked by Wall St. Rank hold RNAC as of Q4 2023.

  • Mackenzie Financial reported no remaining Cartesian Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Mackenzie Financial sold 923 Cartesian Therapeutics shares in Q4 2023, an estimated $26.2K.
  • Mackenzie Financial first reported a position in Cartesian Therapeutics in Q1 2023 and held it in 3 quarters.
  • Mackenzie Financial's Cartesian Therapeutics position peaked at $31K in Q2 2023.
  • 80 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2023.

Based on Mackenzie Financial's 13F filing for Q4 2023, filed 30 Jan 2024.